EXHIBIT 10.62
ALTA BIOPHARMA PARTNERS II, L.P.
MANAGEMENT RIGHTS, INVESTMENTS IN CERTAIN COUNTRIES, AND
INDEMNIFICATION
MANAGEMENT RIGHTS
This agreement will confirm that pursuant to, and effective upon, the purchase
of shares of stock of Orphan Medical, Inc. (the "Company") by Alta BioPharma
Partners II, L.P. (the "Investor"), together with its affiliates, for so long as
Investor owns at least 25% of the shares of Common Stock purchased by Investor
and its affiliates on the Closing Date (as that term is defined in that certain
Stock Purchase Agreement dated December 7, 2001, by and between the Company and
investors listed on Schedule 1 attached thereto), Investor will be entitled to
the following contractual management rights:
1) Investor shall be entitled to consult with and advise management of the
Company on significant business issues, including management's proposed
annual operating plans, and management will meet with Investor
regularly during each year at the Company's facilities at mutually
agreeable times for such consultation and advice and to review progress
in achieving said plans; provided, however, that nothing in this
agreement shall obligate the Company or Company management to act on
any matter as recommended by Investor.
2) Investor may examine the books and records of the Company and inspect
its facilities, and will receive upon request information at reasonable
times and intervals concerning the general status of the Company's
financial condition and operations, provided that access to highly
confidential proprietary information and facilities need not be
provided. The provisions of this paragraph shall survive termination of
this agreement.
3) If Investor is not represented on the Company's Board of Directors, the
Company shall invite a representative of Investor to attend all
meetings of its Board of Directors (and all committees thereof) in a
nonvoting observer capacity and, in this respect, shall give such
representative copies of all notices, minutes, consents and other
material that it provides to its directors; provided, however, that the
Company reserves the right to exclude such representative from access
to any material or meeting or portion thereof if the Company believes
upon the advise of counsel that such exclusion is reasonably necessary
to preserve the attorney client privilege, to protect highly
confidential proprietary information or for other similar reasons. Such
representative may participate in discussions of matters brought to the
Board.
The aforementioned rights are intended to satisfy the requirement of management
rights for purposes of qualifying Investor's ownership of stock in the Company
as a "venture capital investment" for purposes of the Department of Labor "plan
asset" regulations, 29 C.F.R. ss.2510.3-101, and in the event the aforementioned
rights are not satisfactory for such purpose, the Company and Investor shall
reasonably cooperate in good faith to agree upon mutually satisfactory
management rights that satisfy such regulations.
Investor agrees, and any representative of Investor will agree, to hold in
confidence and trust and not use or disclose any confidential information
provided to or learned by it in connection with its rights under this agreement.
The rights described herein are nonassignable and shall terminate and be of no
further force or effect upon the date upon which Investor and its affiliates
ceases to hold at least 25% of the shares of the Company's Common Stock
purchased on the Closing Date (as defined herein). The confidentiality
provisions hereof will survive any such termination.
INVESTMENTS RELATING TO CERTAIN FOREIGN COUNTRIES
The Company hereby represents that it has not participated and is not
participating in, an anti-Israeli boycott within the scope of chapter 7 of Part
2 of Division 4 of Title 2 of the California Government Code as in effect from
time to time.
INDEMNIFICATION
The Company will use its reasonable efforts to limit the liability, to the
fullest extent permissible under the governing law of its state of
incorporation, of any director affiliated with Alta BioPharma Partners II, L.P.
and each of his or her affiliated parties.
Accepted and agreed this 6th day of December, 2001
Orphan Medical, Inc.
By: /s/ ▇▇▇▇ ▇▇▇▇▇▇ Bullion
------------------------------
Title: CEO